• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.

作者信息

Ravnik-Oblak M, Mrevlje F

机构信息

Department of Endocrinology and Metabolism, University Medical Centre Ljubljana, Slovenia.

出版信息

Diabetes Res Clin Pract. 1995 Oct;30(1):27-35. doi: 10.1016/0168-8227(95)01137-4.

DOI:10.1016/0168-8227(95)01137-4
PMID:8745203
Abstract

AIM

Comparison of the effectiveness of combined therapy vs. an insulin regimen in NIDDM patients with secondary failure of oral hypoglycemic agents. RESEARCH DESIGN, PATIENTS AND METHODS: 27 NIDDM patients were randomly allocated to Group A (n = 14, insulin) and Group B (n = 13, insulin and sulfonylurea) with crossover after 3 months. After the next 3 months a decision was made about the further treatment according to the metabolic control. The patients were then treated for another year with the more successful regimen. Metabolic control, residual beta-cell secretory capacity, degree of peripheral insulin resistance (clamp) and insulin dose were followed during the whole study.

RESULTS

(median, interquartile range, in brackets; , statistically significant difference at P < 0.05): the combined therapy was better than insulin alone in 2/3 of patients. Glycemic control was better (HbA1c at 3 months: Group A = 7.9(1.1)% vs. Group B = 7.0(0.5)%; HbA1c at 6 months: Group A = 7.4(1.5)% vs. Group B = 8.1(1.5)%. Insulin dose was lower during the combined therapy in the first 3 months: Group A = 0.62(0.18) U/kg body weight vs. Group B = 0.39(0.16) U/kg body weight*. Combined treatment was associated with increased C-peptide excretion both fasting and postprandially. No significant differences in peripheral insulin resistance were noted between the two groups. The combined treatment remained successful even after one year. The two groups of patients with different effective treatment did not differ significantly in any of the observed parameters.

CONCLUSIONS

the combined therapy was more effective than insulin alone. Its favourable effect persisted after treatment for a year. It seems better to start the treatment of the oral failure with combined therapy compared with insulin first and later followed by combined therapy. On the basis of the observed parameters it is impossible to determine in advance which kind of treatment is more suitable for the individual patient.

摘要

相似文献

1
Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.
Diabetes Res Clin Pract. 1995 Oct;30(1):27-35. doi: 10.1016/0168-8227(95)01137-4.
2
Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.非胰岛素依赖型糖尿病患者中,胰岛淀粉样多肽和胰岛淀粉样多肽样肽浓度的变化以及β细胞功能对磺脲类药物或胰岛素治疗的反应。
Diabetes Care. 1998 May;21(5):810-6. doi: 10.2337/diacare.21.5.810.
3
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.胰岛素联合或不联合口服降糖药持续治疗非胰岛素依赖型糖尿病患者继发性失效的比较。
Diabetes Care. 1995 Mar;18(3):307-14. doi: 10.2337/diacare.18.3.307.
4
Comparison of different insulin regimens in elderly patients with NIDDM.老年非胰岛素依赖型糖尿病患者不同胰岛素治疗方案的比较。
Diabetes Care. 1996 Dec;19(12):1326-32. doi: 10.2337/diacare.19.12.1326.
5
Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.小剂量皮下注射胰岛素作为预防具有非胰岛素依赖型糖尿病临床特征的胰岛细胞抗体阳性患者缓慢进行性β细胞功能衰竭的一种策略。
Diabetes. 1996 May;45(5):622-6. doi: 10.2337/diab.45.5.622.
6
Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or diet alone during the first year of hemodialysis in type 2 diabetic patients with ESRD.在 ESRD 的 2 型糖尿病患者中,在开始血液透析的第一年,与单独使用胰岛素治疗和/或饮食相比,口服降糖药物治疗在代谢控制和血管疾病方面的效果。
Int Urol Nephrol. 2011 Dec;43(4):1155-60. doi: 10.1007/s11255-010-9804-x. Epub 2010 Jul 20.
7
A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.阿卡波糖与二甲双胍作为磺脲类治疗的非胰岛素依赖型糖尿病患者辅助治疗的比较。
Diabetes Care. 1996 Mar;19(3):252-4. doi: 10.2337/diacare.19.3.252.
8
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.英国前瞻性糖尿病研究24:一项为期6年的随机对照试验,比较磺脲类药物、胰岛素和二甲双胍疗法对新诊断的、饮食疗法无法控制的2型糖尿病患者的疗效。英国前瞻性糖尿病研究小组。
Ann Intern Med. 1998 Feb 1;128(3):165-75. doi: 10.7326/0003-4819-128-3-199802010-00001.
9
Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?联合治疗对磺脲类药物继发失效的非胰岛素依赖型糖尿病患者的疗效。是否可预测?
J Endocrinol Invest. 1998 Dec;21(11):744-7. doi: 10.1007/BF03348039.
10
Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.格列吡嗪胃肠道治疗系统对非胰岛素依赖型糖尿病患者血糖控制及胰岛素分泌的疗效、安全性和剂量反应特征。两项多中心、随机、安慰剂对照临床试验的结果。格列吡嗪胃肠道治疗系统研究组
Diabetes Care. 1997 Apr;20(4):597-606. doi: 10.2337/diacare.20.4.597.

引用本文的文献

1
Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review.2型糖尿病中胰岛素单药治疗与胰岛素联合其他降糖药物治疗:一项叙述性综述
Int J Endocrinol Metab. 2018 Apr 21;16(2):e65600. doi: 10.5812/ijem.65600. eCollection 2018 Apr.
2
Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.对于已经接受胰岛素治疗但血糖控制不佳的2型糖尿病患者,胰岛素单药治疗与在胰岛素基础上加用口服降糖药的比较。
Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2.
3
Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial.
接受磺酰脲类药物和胰岛素长期联合治疗的 2 型糖尿病患者停用磺酰脲类药物会导致血糖控制恶化:一项随机对照试验。
Diabetes Metab Syndr Obes. 2015 Mar 2;8:137-45. doi: 10.2147/DMSO.S78008. eCollection 2015.
4
Interventions for latent autoimmune diabetes (LADA) in adults.成人隐匿性自身免疫性糖尿病(LADA)的干预措施。
Cochrane Database Syst Rev. 2011 Sep 7;2011(9):CD006165. doi: 10.1002/14651858.CD006165.pub3.
5
Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents.2型糖尿病患者及口服抗糖尿病药物继发失效患者中未满足的需求。
J Endocrinol Invest. 2008 Apr;31(4):371-9. doi: 10.1007/BF03346373.
6
Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.2型糖尿病患者中胰岛素单药治疗与胰岛素联合口服降糖药治疗的比较
Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD003418. doi: 10.1002/14651858.CD003418.pub2.
7
The role of sulphonylureas in the management of type 2 diabetes mellitus.磺脲类药物在2型糖尿病管理中的作用。
Drugs. 2004;64(12):1339-58. doi: 10.2165/00003495-200464120-00006.